title: Stable expression of human homomeric and heteromeric AMPA receptor subunits in HEK293 cells.
abstract: Human homomeric and heteromeric alpha-amino-3-hydroxy-5-methyl-4-isoxazolepropionate (AMPA)-type glutamate receptors (GluRs) were stably expressed in HEK293 cells with cDNAs encoding the flip splice variant of GluR1, GluR2, GluR3, GluR4 subunit, and the GluR1/GluR2, GluR3/GluR2, and GluR4/GluR2 combination. The lethal combination of GluR2 and GluR4 subunits was found in high expression levels of both receptors. The AMPA-evoked current voltage relationships demonstrated the functional channel properties, such as a double rectification in GluR1, GluR3, and GluR4 receptors, and a linear relation in receptors assembled from GluR2 alone and coexpression of GluR2 with the other subunits. All the transfectants exhibited higher selectivity for AMPA than glutamate in dose-dependent current responses. [3H]AMPA binding revealed that the homomeric and heteromeric receptors displayed a single binding site in Scatchard analysis, with dissociation constant (Kd) values in the range of 14.5-49.3 nM. The Bmax values were in the range of 0.57-7.66 pmol/mg protein. The ligand displacement potency for [3H]AMPA binding was CNQX > glutamate > NS257 in all of the transfectants. These results suggest that stable transformants expressing human homomeric and heteromeric AMPA receptors will be useful tools to define selectivity and potential site of action for AMPA receptor modulators.
authors.affiliation: Department of Molecular and Cellular Biology, Nippon Boehringer Ingelheim Co., Ltd., Kawanishi Pharma Research Institute, Yato, Japan.
authors.forename: S
authors.initials: S
authors.lastname: Nishimura
authors.forename: M
authors.initials: M
authors.lastname: Iizuka
authors.forename: M
authors.initials: M
authors.lastname: Wakamori
authors.forename: I
authors.initials: I
authors.lastname: Akiba
authors.forename: K
authors.initials: K
authors.lastname: Imoto
authors.forename: E L
authors.initials: EL
authors.lastname: Barsoumian
mesh_terms: D018750:6-Cyano-7-nitroquinoxaline-2,3-dione / Q000378:metabolism / Q000494:pharmacology; D017398:Alternative Splicing; D001667:Binding, Competitive; D015153:Blotting, Western; D002460:Cell Line; D004594:Electrophysiology; D018698:Glutamic Acid / Q000378:metabolism / Q000494:pharmacology; D006801:Humans; D007211:Indoles / Q000378:metabolism / Q000494:pharmacology; D007668:Kidney / Q000196:embryology; D007700:Kinetics; D021122:Protein Subunits; D011869:Radioligand Assay; D018091:Receptors, AMPA / Q000819:agonists / Q000037:antagonists & inhibitors / Q000235:genetics / Q000378:metabolism*; D013449:Sulfonamides / Q000378:metabolism / Q000494:pharmacology; D014162:Transfection; D014170:Transformation, Genetic; D018350:alpha-Amino-3-hydroxy-5-methyl-4-isoxazolepropionic Acid / Q000378:metabolism / Q000494:pharmacology
chemical_list: D007211:Indoles; C092656:NS 257; D021122:Protein Subunits; D018091:Receptors, AMPA; D013449:Sulfonamides; D018698:Glutamic Acid; D018750:6-Cyano-7-nitroquinoxaline-2,3-dione; D018350:alpha-Amino-3-hydroxy-5-methyl-4-isoxazolepropionic Acid